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ELEMENTS FROM IN VZTRO STUDIES THAT HELP UNDERSTAND 
THE ACTION OF HEPARINS 
H.C. Hemker, A.V. Bendetowicz, S. BCguin. 
Department of Biochemistry, University of Limburg, P.O. Box 616,6200 MD Maastricht, The 
Netherlands. 
ABSTRACT 
In determining heparin one has the chaise to test a specific activity, such as the 
decay constant of thrombin or factor Xa on a global test such as the aP’IT. The 
best test would be a global test that directly reflects the only important global 
effect, to wit antithrombotic efficiency. Such a test does not yet exist. We propose 
that the thrombin potential, i.e. the time concentration integral of thrombin activity 
appearing in plasma after triggering is a plausible candidate for such a test. 
There are two possible approaches to the study of antithrombotic drugs in general, and to the 
study of LMW heparins in particular. The most direct is to investigate their efficacy in animal 
models, or, even better, in patients. This leads to an immediate answer to the most important 
question: does it work? If it does, as is undoubtedly the case with LMWH, then we are left with 
the question of why. Here answers at different levels of sophistication are possible, that, in the 
end, will show us what the actual relation is between the biochemical properties of a drug and 
the antithrombotic action. Aspirin is the prime example of a drug that was known for a long 
time while the mode of action still remained the subject of research. 
Key words: (Where the concentrations are indicated as follows: H = heparin, A = AT III, C = 
heparin - AT IlI complex, P = heparin binding protein and B = heparin bound to that protein). 
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The second possible approach in finding antithrombotic drugs is to start from a working 
hypothesis on the mode of action, that leads to a model which allows testing. Then one can 
select new drugs on basis of their performance in that model and only afterwards test, in 
animals and humans, those that are working in virro. Antibiotics e.g. are selected on their 
capacity to inhibit growth of microorganisms in vitro. This second approach carries more risks 
and is less direct than the first one. But it also is about a thousand times quicker and cheaper. 
All one needs is a good in vifro model. 
Antithrombotic pharmacology has not been very lucky in defining its models up to the 
present. Platelet aggregation has been the top of the bill for 25 years, without resulting in a drug 
that was manifestely better than aspirin; aspirin not being superior to either heparin or oral 
anticoagulation. 
It also has been conceived that the anti-factor Xa activity in plasma would be a good 
indicator of its antithrombotic power (l-3). We found, however, that inhibition of prothrombin 
conversion in the extrinsic system was hardly inhibited by both UFH and LMWH (4,5). This 
makes it difficult to imagine how anti Xa action could be a measure of antithrombotic activity. 
This immediately led to the next question: If not this, what indeed could be the property of a 
LMWH that determines its efficacy in a patient? For the moment we have no watertight answer. 
Our in vitro studies do suggest a possible approach though. 
In the first articles on low molecular weight heparins the “specific activity” was defined 
as the capacity of heparin to stimulate AT III mediated factor Xa inactivation and it was 
opposed to “anticoagulant activity” which was defined as the capacity to prolong clotting times 
such as the aPTT (2). Even though they wilI not have been meant to do so, these definitions 
automatically suggest that there exists a specific (antithrombotic?) action of heparin as opposed 
to a less relevant anticoagulant activity 
In fact however there are specific effects on inactivation of & of the coagulation 
enzymes. They are specific in the sense that they affect one specific reaction of the overall event 
of coagulation, i.e. 
heparin 
thrombin (or F.Xa or etc.) + AT III ------------> inactive product. 
The action of heparin on each of these reactions can be quantitated in the form of a specific 
constant, as will be discussed below. This gives a set of constants that defines the heparin as to 
its pattern of specific enzyme scavenging. There is no reason whatsoever to assume that any of 
these constants will directly indicate with the overall antithrombotic effect. The fact that penta- 
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saccharide has zero action on thrombin and dermatan sulfate does not act on factor Xa already 
disproves any hypothesis in that direction. 
In order to estimate what the combined effect of all the specific actions is, including their 
secondary effects on feedback activations etc, one will have to measure the final effect, i.e. 
thrombin generation. This has been thought to be assessed with global coagulation assays such 
as aPIT. The fact that neither pentasaccharide m DS will influence this test very much, shows 
that the aFIT is not a good model (and neither is any other coagulation assay, for that matter). 
It is here that we propose the thrombin generation curve as an alternative. 
Heparins increase the decay of clotting factors in plasma. This capacity is reflected in a 
decrease of the halflife time of the factor under study in a plasma containing heparin. Rather 
than t 1~ we prefer to use the pseudo first order decay constant, hec, that is proportional to the 
inverse of the halflife time. Its dimension is inverse time, usually rninl. Heparin activity, and 
therefore bet, increases linearily with the amount of heparin added. The increase of bet per 
unit of weight of heparin therefore indicates how good a heparin is in catalyzing the decay of a 
clotting factor. The actual value is dependent upon the conditions of measurement (see below). 
It is important that kdec should be measured under conditions as near as possible to those 
prevailing in the human in vivo. We should therefore define the specific decav constant of 
heparin for a specific factor, here thrombin, in the following way: 
The thrombin related specific decay constant (IIa-SDC) of a heparin is the increase per j.tg of 
material of the pseudo first order breakdown constant of human thrombin in normal human 
plasma under conditions that are as near as possible to the physiological ones. 
The SDC for other clotting factors can be defiied analogously. Because the dimension of 
the breakdown constant is min- l, the SDC has min-l pg-l as a dimension. The SDC can be 
expressed either per pg of total material or per Itg of high a&ritv ma~(SDC(HAM)). Once 
the SDC has been defined there is no use to express the potency of a heparin in anti-Xa or anti- 
thrombin units any more. It is still useful1 however to compare the activity of given preparation 
to that of a suitable standard, were it only to check the laboratory procedures. 
Much of the confusion in the field of heparins arises from the fact that we are repeatedly, 
and often even unconsciously, switching back and forth between the measuring of effects of 
heparin and interpretation of the importance of these effects. It therefore seems useful to define 
a unit of hem that is independent of any mechanistic interpretation of the mode of action of 
heparin. Starting from the observation that heparins, like oral anticoagulation, hirudin, 
dermatan sulfate etc. etc., work by diminishing the amount of active thrombin that generates in 
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clotting plasma, we define &.JQQJ& as follows: One ZCso unit of heparin is that amount of 
heparin that has to be added to I ml of plasma in or&r to inhibit for 50% the generation of 
thrombin in normal plasma. 
It is interesting to note that it hardly seems to matter, as far as our experience goes, whether one 
measures the inhibition of the thrombin peak or the area under the thrombin generation curve. 
Yet there are practical reasons to prefer the area under the curve: We found that if the 
experimental conditions are kept constant the peak of the curve correlates perfectly with the 
surface, but the peak is subject to variation of thromboplastin concentration and the surface is 
not. Also the experimental error in determining the surface is smaller and it is possible to device 
a simple test that measures it directly. 
As far as our experience goes the dose-effect relationship for hepatitis and the surface 
under the curve is linear on a log-log plot and pamIle1 for different types of heparin. 
The relation between s.pec#ic uobal effects. 
Of course there is a direct relation between the ensemble of specific decay constants (IIa, 
Xa, IXa) and the global effect of a heparin. However direct, it is not necessarily linear or even 
simple. The anti-Xa action of a heparin for instance is not immediately reflected in inhibition of 
thrombin generation. This surprized at first, but appears a posteriori. to be quite logical as we 
will show now. 
We recall that we developed a method to determine the course of prothrombinase activity in 
clotting plasma. The basic principle is that we determine the experimentally found velocity of 
change of thrombin concentration (vexI,). Knowing the decay constant of thrombin in plasma 
we calculate the thrombin breakdown velocity (vdec) (vk = & [Tl, where [Tl represents the 
concentration of thrombin). The prothrombin conversion velocity then equals the experimental 
velocity plus the decay velocity - dP/dt = vexp+ bw [TJ. 
The decay constant of thrombin in plasma (k& is determined in a separate experiment. 
For full details on the method see ref. 6. With this method we showed that the course of 
extrinsically triggered prothrombin conversion under the influence of heparin was only 
marginally inhibited by heparin ( 43). Most low molecular weight heparins did not or hardly 
inhibit prothrombinase activity either. In view to the relatively high anti-Xa action of LMWHs 
as compared to UFH this was an unexpected result. In view of the allegedly therapeutic 
importance of anti-factor Xa action(s) it was even disturbing (1,2). In the light of our know- 
ledge of the physiology of prothrombin conversion, this result is readily explained however. 
We showed as early as 1968 that the prothrombinase complex forms from its three 
components (factor Xa, factor Va and phospholipid) by equilibrium reactions (7). This means 
that the amount of prothrombinase formed when two components are fixed and the third one 
varies, will show saturation kinetics. Later studies gave the reaction constants of prothrombin 
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conversion (8). This allows us to calculate the molar concentration of prothrombinase complex 
in clotting plasma from the rate of prothrombin conversion. At the moment of maximum 
activity the velocity of prothrombin conversion is w 200 nM/min (4). The phospholipid 
concentration is w 1 PM and the remaining concentration of prothrombin is about 1 PM- We 
know from ref. 8 that under these conditions Km = 0.2 p,M and kcat = 20OO.min. We also 
know that the system follows Michaelis-Menten kinetics, so that we can calculate the enzyme 
concentration from the formula v=(kcatE.S.)/(K,+S). In this way we find the prothrombinase 
concentration to be 0.3 nM. We further know that the prothrombinase activity is critically 
dependent upon the appearance of factor Va, (9) and that the fraction Xa concentration has a 
peak value of around 10 nM (10). It follows that the concentration of factor Va must be about 
0.3 nM. Knowing that the & of factor Va and factor Xa under these conditions is 0.3 nM (1 l), 
one can calculate the relations between factor Xa concentration and prothrombinase 
concentration (Fig. 1). From this curve one can determine what the relation between inhibition 
of factor Xa and prothrombin is (Fig. 2). 
. . Fig. 1 The of Drothromblnase as a function of w Xa . concentration . 
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It appears that factor Xa has to be inhibited 85% before prothrombinase inhibition will rise 
above 10%. This general conclusion is largely independent on the actual numerical values of 
the kinetic constants, provided that they are of the order of magnitude indicated. 
It thus appears that there is no discrepancy between the fact that heparins, especially 
LMWH, do increase the decay of factor Xa in plasma, and the observation that this decay is 
hardly reflected in a decrease of the velocity of prothrombin conversion. 
In Fig. 2 we also plotted (from ref. 4) the inhibition of prothrombinase against the 
inhibition of the thrombin peak. The inhibition of the thrombin peak we have shown to be 
directly proportional to the antithrombin activity in the plasma. The antithrombin activity itself 
is proportional to the anti Xa activity, or in the case of UFH even identical. Inhibition of the Xa 
activity therefore should be proportional to the inhibition of the thrombin peak but m to 
inhibition of prothrombinase. Figure 2 shows that this is indeed what has been found in 
clotting plasma. It thus seems that the calculations based on observations on the enzymatology 
of prothrombinase do apply to the situation in plasma. 
. . Cal condrnons. 
Recent work from our laboratory shows that the measuring of anti factor Xa and 
antithrombin activities according to the general practice of the clinical laboratory may be only 
remotely related to the actual decay of these factors in clotting human plasma (Lindhout, 
Beguin, unpublished). This will be discussed elsewhere. Here we want to focus on the action 
of heparin binding proteins in plasma 
Heparin binds reversibly to AT III. Half saturation is seen at - 20 nM of heparin. The 
heparin - AT III complex in a purified systems has a specific activity of about 200 min-l.U-l. 
In plasma however, the heparin is partitioned between AT III and other heparin binding 
proteins such as histidin rich glycoprotein, vitronectin and others (10-20). The two relevant 
reactions are: 
Heparin + antithrombin III + hep - AT III complex 
Heparin + binding protein + complex without heparin activity 
This situation is analogous to classical competitive enzyme inhibition with AT III in the role of 
substrate, the heparin binding protein in the role of inhibitor and heparin as the enzyme , so that 
in fair approximation: C = TA/ (K(1 + (P/M)) + A) 
The efficiency of the inhibitory effect of heparin binding proteins on heparin action is 
determined by the amount of protein (P), and by the dissociation constant of the protein for the 
heparin (M) relative to the dissociation constant of AT III for heparin (IQ. 
We define the “efficiency factor” F = 1 + P/M. This is the factor by which the actual heparin 
concentration in the plasma has to be devided in order to obtain the heparin concentration that 
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would be equipotent if no heparin binding proteins other then AT III would be present. For the 
two most avid heparin binders (vitronectin and histidin rich glycoprotein) this factor to be 60 
and 200 respectively. Heparin also interacts with albumin, fibrinogen, fibronectin and 
lipoproteins. It thus does not seem far fetched to estimate the complete effect as a 300400 fold 
decrease of the efficacy of heparin as compared to a purified system. In the concentration range 
of antithrombin in clotting plasma (3-l PM) the fraction of heparin that is bound will be 
roughly proportional to the amount of AT III present as well as proportional to the amount of 
heparin added. 
From the above paragraphs it will be clear that an acceptable in vitro model of 
antithrombotic potency should be a global test, encompassing the whole mechanism of 
coagulation and also a test carried out in a medium that is as near as possible to plasma. 
In order to check whether any proposed test it is an acceptable candidate for a model, 
there should be no known antithrombotics that do not influence it. If we exclude Aspirin from 
the list, the claim for universality can be restricted to a large subclass of antithrombotics, i.e. 
the anticoagulants. As will be clear from the above we propose the thrombin potential, that is: 
the surface under the thrombin generation curve, as a possible parameter that reflects 
antithrombotic potency. The reason why we propose the surface is that we want an 
experimental value that is proportional to both the amount of thrombin and the duration of its 
action. Thrombin being an enzyme, its concentration as well as the the time during which it is 
active determine its effect. A simple method to estimate the concentration-time interval of 
thrombin - that we called the thrombin potential, will be published elsewhere. We found that 
the thrombin potential is diminished by oral anticoagulation, all heparins, hirudin, dermatan 
sulfate lactobionic acid and, in short, every anticoagulant that we tested. 
Whether is a representative in vitro parameter of antithrombotic efficacy should follow 
from studies on its correlation in vivo inhibition of thrombosis. 
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